mRNA-1345
Phase 3Completed 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus
Conditions
Respiratory Syncytial Virus
Trial Timeline
Nov 17, 2021 → Jul 28, 2025
NCT ID
NCT05127434About mRNA-1345
mRNA-1345 is a phase 3 stage product being developed by Moderna for Respiratory Syncytial Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT05127434. Target conditions include Respiratory Syncytial Virus.
What happened to similar drugs?
10 of 20 similar drugs in Respiratory Syncytial Virus were approved
Approved (10) Terminated (3) Active (9)
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07117487 | Phase 3 | Active |
| NCT06143046 | Phase 2 | Active |
| NCT06097299 | Phase 2 | Completed |
| NCT06067230 | Phase 3 | Active |
| NCT06060457 | Phase 3 | Completed |
| NCT05743881 | Phase 1 | Active |
| NCT05572658 | Preclinical | Completed |
| NCT05330975 | Phase 3 | Completed |
| NCT05127434 | Phase 3 | Completed |
| NCT04528719 | Phase 1 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Preclinical | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 44 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 30 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 19 |
| YMC026 + Placebo | Yuhan | Approved | 43 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 35 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 32 |
| S-337395 + Placebo | Shionogi | Phase 2 | 42 |
| Sivelestat | Eli Lilly | Phase 1/2 | 32 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 35 |